NCT01643668View on ClinicalTrials.gov

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Busulfan

Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation

DRUG

Clofarabine

Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation

PROCEDURE

Allogeneic Stem Cell Infusion

Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01643668 - Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter